Lyra Therapeutics board members Altman and Poukalov resign; board rebalanced

Lyra Therapeutics, Inc.

Michael Altman and Konstantin Poukalov resigned from Lyra Therapeutics Board effective December 12, 2024.
Maria Palasis, Ph.D. moved from Class III to Class I director to rebalance board classes; term extended to 2027.
Board now consists of two Class I, two Class II, and two Class III directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.